Cite
HARVARD Citation
Icht, O. et al. (2021). Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non‐small‐cell lung cancer. Asia-Pacific journal of clinical oncology. 17 (2), pp. e125-e131. [Online].